Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,763 total articles
Amentum's recent contract wins and the Torus defence supply chain alliance reinforce our thesis that the company’s backlog and services focus will support revenue visibility into 2027. The stock is recovering from oversold territory but still trades below recent highs; we outline a long trade with defined entry, targets, and stop loss tied to contr…
LENZ Therapeutics is a pre-commercial eye-care biotech trading at a $286M market cap after a rocky launch quarter and a recent earnings miss. The company’s lead candidate, LNZ100, has strong Phase 3 data and prescription momentum signals (VIZZ scripts), while fundamentals show a stretched cash profile and heavy shorts. This is a speculative, high-r…
Lonza (LZAGF) looks like an actionable long after a period of weakness. Corporate refocus following the CHI exit reduces distraction and should improve execution on higher-margin lines. Technicals show bullish momentum (MACD histogram positive, price holding above 10/20-day averages) while the 50-day still offers upside near-term. Elevated short in…
Micron is getting punished on fears that compression algorithms and aggressive capex will cap memory pricing. The fundamentals and cash-flow profile argue the pullback is an overreaction. This trade buys a disciplined dip: enter $340.00, stop $305.00, target $460.00 over a 180-trading-day horizon.
Adeia (ADEA) is a small-cap technology licensor whose hybrid bonding and 3D integration patents are finding renewed commercial traction. Recent multi-year renewals, a new agreement with UMC, improving free cash flow and an expanding addressable market for chiplet architectures create a path for upside. This trade idea lays out an actionable entry, …
Credo Technology is a core AI-infrastructure supplier showing explosive revenue growth and industry-leading gross margins, but the stock has been punished by momentum and sentiment despite healthy cash flow and a clean balance sheet. This trade idea lays out a size-up plan with entry, stop, and target prices across time horizons while highlighting …
Boston Scientific (BSX) has moved from a hypergrowth narrative centered on electrophysiology into a more diversified, cash-generative company. A sell-off after trial readouts and guidance misses created a buying opportunity at about $63. This trade idea frames a long position aimed at riding valuation re-rating and durable compounding over the next…
Dana's recent margin expansion, a 20% dividend hike and an expanded $2B repurchase plan signal management confidence. With free cash flow near $298M and EV/EBITDA around 10x, the stock looks attractive for a mid-term swing trade while structural liabilities keep risk elevated.
First Solar trades at a reasonable multiple with strong free cash flow and a lean balance sheet. Rising fossil fuel prices and constrained generation capacity make utility-scale solar attractive to power buyers even as federal tax incentives wane. This trade idea lays out an actionable long with entry, stop and target, plus the catalysts and risks …
The Iran war shock has repriced risk across aviation, but Boeing's mix of commercial deliveries, defense revenue and services gives it a pathway back to growth. The stock trades at $202 with stretched multiples and weak near-term cash flow, yet order momentum (including recent airline fleet expansions and freighter demand) plus a manageable short-i…
IBEX Ltd. ($IBEX) combines a low-leverage balance sheet, strong cash flow and improving AI-powered digital services to target growing healthtech CX and diagnostics workflows. The company trades at an attractive multiple relative to fundamentals. This trade idea proposes a long entry at $26.81, a stop at $24.50 and a target of $36.00 over a long-ter…
Domino's has continued to out-execute peers in a tough restaurant market, producing healthy free cash flow and stable same-store momentum while trading at roughly 20x earnings and an EV/EBITDA of ~16. I recommend a swing-long entry to capture a likely re-rating as investor confidence returns and operational tailwinds persist.
Amphenol (APH) is a high-quality industrial technology compounder with a diversified product mix across harsh-environment connectors, communications hardware, and sensors. Recent macro trends - accelerated AI infrastructure spending, 5G densification and long-term growth in electrification - play directly to Amphenol's strengths. The pullback after…
<p>Kratos is trading at a discount to the optionality it carries in hypersonics, unmanned systems and non-terrestrial networks. Strong backlog, a $13.7B pipeline and low leverage give the company room to execute while the broader defense cycle and program awards should re-rate the stock if execution continues.</p>
Dine Brands (DIN) offers a tactical long opportunity: the market is pricing the company like a shrinking restaurant operator while its business generates healthy free cash flow and carries an enterprise value that suggests embedded real-estate and rental optionality. This trade targets a re-rating into the mid-$30s over the next 45 trading days whi…
Lam Research (LRCX) is sitting on durable secular demand from AI-driven memory and logic capex while recent momentum and technicals show short-term turbulence. For disciplined traders, a mid-term swing entry at $218 with a $260 target and $185 stop offers a favorable reward-to-risk given robust free cash flow, high ROE, and fresh capex tailwinds fr…
Sprouts Farmers Market offers durable, differentiated grocery exposure (fresh, natural, organic) with strong free cash flow, low debt and profitable margins. The stock is trading near $77 after a 60% drawdown from its $182 52-week high; fundamentals argue for a re-rating toward mid-teens multiples. This is a tactical long: entry $77.15, stop $68.00…
Sandisk (SNDK) is a pure-play NAND flash storage company trading at a premium, but with $1.45B in free cash flow, a clean balance sheet and direct exposure to AI/datacenter spend. I recommend a long trade with an entry at $645.00, a $780.00 target and a $520.00 stop over a long-term horizon (180 trading days).
NIQ Global Intelligence looks materially undervalued on cash-flow metrics despite a negative EPS and elevated leverage. Today's breakout on above-average volume gives a practical entry for a swing trade aiming for a re-rating as AI-driven product adoption and FCF conversion meet investor attention.
Hecla's divestiture of Casa Berardi turns the company into a tighter precious-metals producer with a cleaner balance sheet. With low leverage, positive free cash flow ($310M), and a market cap near $12.5B, Hecla offers asymmetric upside if silver and gold stabilize. This is a mid-term swing trade designed to capture a re-rating as the market re-pri…
TG Therapeutics' BRIUMVI continues to drive outsized top-line growth, management is leaning into commercial expansion and awareness campaigns, and the stock trades at a reasonable P/E for a growth-to-profit story. We recommend a tactical long with a $33.20 entry, $46.48 target and $29.00 stop, horizon ~180 trading days.
Deere & Company is showing fresh positive signals: renewed analyst optimism after February results, dividend support, and industry tailwinds in agricultural robots and autonomous construction equipment. The stock pulled back from its 52-week high but is trading on solid fundamentals - PE ~31, ROE ~18%, and $3.58B of free cash flow. This trade targe…
Meta ($META) looks vulnerable despite recent strength. Fundamentals are solid but priced for perfection: P/E ~22.8, P/S ~6.8 and stretched technicals leave room for a re-test of the low $400s if ad growth disappoints or Reality Labs costs re-emerge. This is a mid-term (45 trading days) actionable short with defined entry, stop and target sized for …
First Solar (FSLR) is a rare large-cap solar manufacturer that remains profitable, cash-flow positive, and undervalued versus its history and cash-generation profile. After a pullback tied to conservative 2026 guidance and political uncertainty over tax credits, the stock looks buyable at current levels: cheap on P/E, reasonable EV/EBITDA, strong b…
Myriad trades at a sub-0.5x price-to-sales multiple and an enterprise value of roughly $378M. A modest re‑rating toward 1.0x–1.5x P/S driven by MRD commercialization and reimbursement wins would imply meaningful upside from today's $4.50 share price. This trade idea buys the optionality with a defined stop and a clear multi-month horizon.
